Literature DB >> 23690466

Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.

Ricardo Villa-Bellosta1, José Rivera-Torres, Fernando G Osorio, Rebeca Acín-Pérez, José A Enriquez, Carlos López-Otín, Vicente Andrés.   

Abstract

BACKGROUND: Progerin is a mutant form of lamin A responsible for Hutchinson-Gilford progeria syndrome (HGPS), a premature aging disorder characterized by excessive atherosclerosis and vascular calcification that leads to premature death, predominantly of myocardial infarction or stroke. The goal of this study was to investigate mechanisms that cause excessive vascular calcification in HGPS. METHODS AND
RESULTS: We performed expression and functional studies in wild-type mice and knock-in Lmna(G609G/+) mice expressing progerin, which mimic the main clinical manifestations of HGPS. Lmna(G609G/+) mice showed excessive aortic calcification, and primary aortic vascular smooth muscle cells from these progeroid animals had an impaired capacity to inhibit vascular calcification. This defect in progerin-expressing vascular smooth muscle cells is associated with increased expression and activity of tissue-nonspecific alkaline phosphatase and mitochondrial dysfunction, which leads to reduced ATP synthesis. Accordingly, Lmna(G609G/+) vascular smooth muscle cells are defective for the production and extracellular accumulation of pyrophosphate, a major inhibitor of vascular calcification. We also found increased alkaline phosphatase activity and reduced ATP and pyrophosphate levels in plasma of Lmna(G609G/+) mice without changes in phosphorus and calcium. Treatment with pyrophosphate inhibited vascular calcification in progeroid mice.
CONCLUSIONS: Excessive vascular calcification in Lmna(G609G) mice is caused by reduced extracellular accumulation of pyrophosphate that results from increased tissue-nonspecific alkaline phosphatase activity and diminished ATP availability caused by mitochondrial dysfunction in vascular smooth muscle cells. Excessive calcification is ameliorated on pyrophosphate treatment. These findings reveal a previously undefined pathogenic process in HGPS that may also contribute to vascular calcification in normal aging, because progerin progressively accumulates in the vascular tissue of individuals without HGPS.

Entities:  

Keywords:  ATP; Hutchinson-Gilford progeria syndrome; muscle, smooth; progerin; pyrophosphate; tissue-non specific alkaline phosphatase; vascular calcification

Mesh:

Substances:

Year:  2013        PMID: 23690466     DOI: 10.1161/CIRCULATIONAHA.112.000571

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  82 in total

Review 1.  Inherited Arterial Calcification Syndromes: Etiologies and Treatment Concepts.

Authors:  Yvonne Nitschke; Frank Rutsch
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 2.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

3.  Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.

Authors:  Leslie B Gordon; Monica E Kleinman; Joe Massaro; Ralph B D'Agostino; Heather Shappell; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert H Cleveland; Ara Nazarian; Brian D Snyder; Nicole J Ullrich; V Michelle Silvera; Marilyn G Liang; Nicolle Quinn; David T Miller; Susanna Y Huh; Anne A Dowton; Kelly Littlefield; Maya M Greer; Mark W Kieran
Journal:  Circulation       Date:  2016-07-12       Impact factor: 29.690

4.  Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1.

Authors:  Haoyue Zhang; Zheng-Mei Xiong; Kan Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 5.  Chronic kidney disease and premature ageing.

Authors:  Jeroen P Kooman; Peter Kotanko; Annemie M W J Schols; Paul G Shiels; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2014-10-07       Impact factor: 28.314

Review 6.  Cockayne syndrome: Clinical features, model systems and pathways.

Authors:  Ajoy C Karikkineth; Morten Scheibye-Knudsen; Elayne Fivenson; Deborah L Croteau; Vilhelm A Bohr
Journal:  Ageing Res Rev       Date:  2016-08-06       Impact factor: 10.895

7.  Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations.

Authors:  José Rivera-Torres; Conrado J Calvo; Anna Llach; Gabriela Guzmán-Martínez; Ricardo Caballero; Cristina González-Gómez; Luis J Jiménez-Borreguero; Juan A Guadix; Fernando G Osorio; Carlos López-Otín; Adela Herraiz-Martínez; Nuria Cabello; Alex Vallmitjana; Raul Benítez; Leslie B Gordon; José Jalife; José M Pérez-Pomares; Juan Tamargo; Eva Delpón; Leif Hove-Madsen; David Filgueiras-Rama; Vicente Andrés
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 8.  Vascular calcification: Mechanisms of vascular smooth muscle cell calcification.

Authors:  Jane A Leopold
Journal:  Trends Cardiovasc Med       Date:  2014-10-30       Impact factor: 6.677

Review 9.  DNA repair defects and genome instability in Hutchinson-Gilford Progeria Syndrome.

Authors:  Susana Gonzalo; Ray Kreienkamp
Journal:  Curr Opin Cell Biol       Date:  2015-06-12       Impact factor: 8.382

10.  Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.

Authors:  C M Gordon; R H Cleveland; K Baltrusaitis; J Massaro; R B D'Agostino; M G Liang; B Snyder; M Walters; X Li; D T Braddock; M E Kleinman; M W Kieran; L B Gordon
Journal:  Bone       Date:  2019-05-08       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.